{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:02:15Z","timestamp":1775235735948,"version":"3.50.1"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Translocator protein 18 kDa (TSPO) is a promising target for the creation of\neffective and safe neuropsychotropic drugs. The ligands of TSPO exhibit anxiolytic, antidepressant,\nneuroprotective and other activities without the side effects of benzodiazepines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>New TSPO ligands in the series of N,1-diphenylpyrrolo[1,2-a]pyrazine-3-carboxamides\nderivatives were designed using calculated pharmacophore model and molecular docking analysis.\nThe synthesis of new compounds was carried out by two schemes using [3+3]-cycloaddition reaction\nof 2-azidoacrylic acid derivatives with pyrrolphenylketone as a key stage. The anxiolytic activity of\nnew substances has been established using open field test with flash.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Several synthesized N,1-diphenylpyrrolo[1,2-a]pyrazine-3-carboxamides derivatives significantly\nincreased the total motor activity of Balb\/c mice compared to the control. The structureactivity\nrelationship was investigated. The most effective compound was found to be GML-11 (Nbenzyl-\nN,1-diphenylpyrrolo[1,2-a]pyrazine-3-carboxamide), which had anxiolytic action in the dose\nrange from 0.001 to 0.100 mg\/kg (Balb\/c, i.p.). This compound is two orders of magnitude higher in\ndose activity than all other pyrrolo[1,2-a]pyrazine TSPO ligands.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Molecular modelling methods allowed us to create new TSPO ligands in the series of\nN,1-diphenylpyrrolo[1,2-a]pyrazine-3-carboxamides with high anxiolytic activity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406417666210806095051","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T04:39:22Z","timestamp":1628483962000},"page":"497-508","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Design, Synthesis and Pharmacological Activity of New Pyrrolo[1,2-A]\nPyrazine Translocator Protein (TSPO) Ligands"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0334","authenticated-orcid":true,"given":"Grigory","family":"Mokrov","sequence":"first","affiliation":[{"name":"FSBI Zakusov Research Institute of Pharmacology, Baltiyskaya 8, Moscow 125315, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-594X","authenticated-orcid":true,"given":"Andry","family":"Pantileev","sequence":"additional","affiliation":[{"name":"FSBI Zakusov Research Institute of Pharmacology, Baltiyskaya 8, Moscow 125315, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-5786","authenticated-orcid":true,"given":"Milada","family":"Yarkova","sequence":"additional","affiliation":[{"name":"FSBI Zakusov Research Institute of Pharmacology, Baltiyskaya 8, Moscow 125315, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-4474","authenticated-orcid":true,"given":"Tatiana","family":"Gudasheva","sequence":"additional","affiliation":[{"name":"FSBI Zakusov Research Institute of Pharmacology, Baltiyskaya 8, Moscow 125315, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4482-9331","authenticated-orcid":true,"given":"Sergei","family":"Seredenin","sequence":"additional","affiliation":[{"name":"FSBI Zakusov Research Institute of Pharmacology, Baltiyskaya 8, Moscow 125315, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/1381612826666200903122025","volume":"27","author":"Mokrov G.V.","year":"2021","unstructured":"Mokrov G.V.; Deeva O.A.; Gudasheva T.A.; The ligands of translocator protein: Design and biological properties. Curr Pharm Des 2021,27(2),217-237","journal-title":"Curr Pharm Des"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/toxics9020025","volume":"9","author":"Sanabria E.","year":"2021","unstructured":"Sanabria E.; Cuenca R.E.; Esteso M.\u00c1.; Maldonado M.; Benzodiazepines: Their use either as essential medicines or as toxics substances. Toxics 2021,9(2),25","journal-title":"Toxics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd3295","volume":"9","author":"Rupprecht R.","year":"2010","unstructured":"Rupprecht R.; Papadopoulos V.; Rammes G.; Baghai T.C.; Fan J.; Akula N.; Groyer G.; Adams D.; Schumacher M.; Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010,9(12),971-988","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.55331","volume":"9","author":"Sugasawa Y.","year":"2020","unstructured":"Sugasawa Y.; Cheng W.W.L.; Bracamontes J.R.; Chen Z.W.; Wang L.; Germann A.L.; Pierce S.R.; Senneff T.C.; Krishnan K.; Reichert D.E.; Covey D.F.; Akk G.; Evers A.S.; Site-specific effects of neurosteroids on GABAA receptor activation and desensitization. eLife 2020,9,1-32","journal-title":"eLife"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsbmb.2014.09.001","volume":"146","author":"Guennoun R.","year":"2015","unstructured":"Guennoun R.; Labombarda F.; Gonzalez Deniselle M.C.; Liere P.; De Nicola A.F.; Schumacher M.; Progesterone and allopregnanolone in the central nervous system: Response to injury and implication for neuroprotection. J Steroid Biochem Mol Biol 2015,146,48-61","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=6","first-page":"325, 490","author":"Rupprecht R.","year":"2009","unstructured":"Rupprecht R.; Ranimes G.; Eser D.; Baghai T.C.; Schule C.; Nothdurfter C.; Troxler T.; Gentsch C.; Kalkman H.O.; Chaperon F.; Uzunov V.; McAllister K.H.; Bertaina-Anglade V.; La Rochelle C.D.; Tuerck D.; Floesser A.; Kiese B.; Schumacher M.; Landgraf R.; Holsboer F.; Kucher K.; Translocator protein (18kd) as target for anxiolytics without benzodiazepine-like side effects. Science (80- ) 2009,325, 490-493","journal-title":"Science (80- )"},{"key":"ref=7","first-page":"426","volume":"12","author":"Da Pozzo E.","year":"2012","unstructured":"Da Pozzo E.; Costa B.; Martini C.; Translocator protein (TSPO) and neurosteroids: Implications in psychiatric disorders. Curr Mol Med 2012,12(4),426-442","journal-title":"Curr Mol Med"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112924","volume":"209","author":"Barresi E.","year":"2021","unstructured":"Barresi E.; Robello M.; Costa B.; Da Pozzo E.; Baglini E.; Salerno S.; Da Settimo F.; Martini C.; Taliani S.; An update into the medicinal chemistry of translocator protein (TSPO) ligands. Eur J Med Chem 2021,209","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1016\/j.bmc.2015.04.049","volume":"23","author":"Mokrov G.V.","year":"2015","unstructured":"Mokrov G.V.; Deeva O.A.; Gudasheva T.A.; Yarkov S.A.; Yarkova M.A.; Seredenin S.B.; Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides. Bioorg Med Chem 2015,23(13),3368-3378","journal-title":"Bioorg Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/1573406415666181119164846","volume":"15","author":"Gudasheva T.A.","year":"2019","unstructured":"Gudasheva T.A.; Deeva O.A.; Mokrov G.V.; Dyabina A.S.; Yarkova M.A.; Seredenin S.B.; Design, synthesis and anxiolytic activity evaluation of n-acyltryptophanyl- containing dipeptides, potential tspo ligands. Med Chem 2019,15(4),383-399","journal-title":"Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/molecules25215132","volume":"25","author":"Gudasheva T.A.","year":"2020","unstructured":"Gudasheva T.A.; Deeva O.A.; Pantileev A.S.; Mokrov G.V.; Rybina I.V.; Yarkova M.A.; Seredenin S.B.; The new dipeptide tspo ligands: Design, synthesis and structure-anxiolytic activity relationship. Molecules 2020,25(21),25","journal-title":"Molecules"},{"key":"ref=12","first-page":"7","volume":"79","author":"Yarkov S.A.","year":"2016","unstructured":"Yarkov S.A.; Mokrov G.V.; Gudasheva T.A.; Yarkova M.A.; Seredenin S.B.; Pharmacological study of new compounds acting as regulators of 18-kda translocator protein ligands (In Russ.). Eksp Klin Farmakol 2016,79(1),7-11","journal-title":"Eksp Klin Farmakol"},{"key":"ref=13","first-page":"3","volume":"80","author":"Yarkova M.A.","year":"2017","unstructured":"Yarkova M.A.; Povarnina P.Y.; Mokrov G.; Gudasheva T.A.; Seredenin S.B.; Antidepressant and nootrope effects of original tspo ligands (in Russ.). Eksp Klin Farmakol 2017,80,3-7","journal-title":"Eksp Klin Farmakol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11094-016-1476-0","volume":"50","author":"Yarkova M.A.","year":"2016","unstructured":"Yarkova M.A.; Mokrov G.V.; Gudasheva T.A.; Seredenin S.B.; Novel pyrrolo[1,2-a]pyrazines (tspo ligands) with anxiolytic activity dependent on neurosteroid biosynthesis. Pharm Chem J 2016,50,501-504","journal-title":"Pharm Chem J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.2174\/156802611795165142","volume":"11","author":"Taliani S.","year":"2011","unstructured":"Taliani S.; Pugliesi I.; Da Settimo F.; Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO). Ligands Curr Top Med Chem 2011,11(7),860-886","journal-title":"Ligands Curr Top Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s11064-020-03036-9","volume":"45","author":"Ren P.","year":"2020","unstructured":"Ren P.; Ma L.; Wang J.Y.; Guo H.; Sun L.; Gao M.L.; Liu Y.Z.; Ma Y.Q.; Li Y.F.; Guo W.Z.; Anxiolytic and anti-depressive like effects of translocator protein (18 kda) ligand yl-ipa08 in a rat model of postpartum depression. Neurochem Res 2020,45(8),1746-1757","journal-title":"Neurochem Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuropharm.2013.09.016","volume":"81","author":"Zhang L.M.","year":"2014","unstructured":"Zhang L.M.; Zhao N.; Guo W.Z.; Jin Z.L.; Qiu Z.K.; Chen H.X.; Xue R.; Zhang Y.Z.; Yang R.F.; Li Y.F.; Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa). Neuropharmacology 2014,81,116-125","journal-title":"Neuropharmacology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjp.0702530","volume":"127","author":"Serra M.","year":"1999","unstructured":"Serra M.; Madau P.; Chessa M.F.; Caddeo M.; Sanna E.; Trapani G.; Franco M.; Liso G.; Purdy R.H.; Barbaccia M.L.; Biggio G.; 2-Phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: Stimulation of neurosteroid synthesis and anticonflict action in rats. Br J Pharmacol 1999,127(1),177-187","journal-title":"Br J Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0028-3908(99)00253-1","volume":"39","author":"Schlichter R.","year":"2000","unstructured":"Schlichter R.; Rybalchenko V.; Poisbeau P.; Verleye M.; Gillardin J.; Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 2000,39(9),1523-1535","journal-title":"Neuropharmacology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1007\/s00213-020-05617-6","volume":"237","author":"Vicente B.","year":"2020","unstructured":"Vicente B.; Saldivia S.; Hormazabal N.; Bustos C.; Rub\u00ed P.; Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: A randomized, double blind, non-inferiority trial. Psychopharmacology (Berl) 2020,237(11),3357-3367","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuropharm.2015.07.011","volume":"99","author":"Mitsui K.","year":"2015","unstructured":"Mitsui K.; Niwa T.; Kawahara Y.; Morimoto N.; Ohmoto K.; Kato M.; Yamaura Y.; Yoshimoto N.; Suna H.; Katsumata S.; Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology 2015,99,51-66","journal-title":"Neuropharmacology"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107835","volume":"162","author":"Nozaki K.","year":"2020","unstructured":"Nozaki K.; Ito H.; Ohgidani M.; Yamawaki Y.; Sahin E.H.; Kitajima T.; Katsumata S.; Yamawaki S.; Kato T.A.; Aizawa H.; Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress. Neuropharmacology 2020,162","journal-title":"Neuropharmacology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pbb.2018.04.007","volume":"171","author":"Lima-Maximino M.G.","year":"2018","unstructured":"Lima-Maximino M.G.; Cueto-Escobedo J.; Rodr\u00edguez-Landa J.F.; Maximino C.; FGIN-1-27, an agonist at translocator protein 18\u202fkDa (TSPO), produces anti-anxiety and anti-panic effects in non-mammalian models. Pharmacol Biochem Behav 2018,171,66-73","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1021\/jm00072a010","volume":"36","author":"Kozikowski A.P.","year":"1993","unstructured":"Kozikowski A.P.; Ma D.; Brewer J.; Sun S.; Costa E.; Romeo E.; Guidotti A.; Chemistry, binding affinities, and behavioral properties of a new class of \u201cantineophobic\u201d mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem 1993,36(20),2908-2920","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bmc.2003.10.050","volume":"12","author":"Okubo T.","year":"2004","unstructured":"Okubo T.; Yoshikawa R.; Chaki S.; Okuyama S.; Nakazato A.; Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands. Bioorg Med Chem 2004,12(2),423-438","journal-title":"Bioorg Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1073\/pnas.74.9.3805","volume":"74","author":"Braestrup C.","year":"1977","unstructured":"Braestrup C.; Squires R.F.; Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA 1977,74(9),3805-3809","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.neuroscience.2009.08.005","volume":"164","author":"Giatti S.","year":"2009","unstructured":"Giatti S.; Pesaresi M.; Cavaletti G.; Bianchi R.; Carozzi V.; Lombardi R.; Maschi O.; Lauria G.; Garcia-Segura L.M.; Caruso D.; Melcangi R.C.; Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009,164(2),520-529","journal-title":"Neuroscience"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/S0968-0896(01)00192-4","volume":"9","author":"Selleri S.","year":"2001","unstructured":"Selleri S.; Bruni F.; Costagli C.; Costanzo A.; Guerrini G.; Ciciani G.; Costa B.; Martini C.; 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg Med Chem 2001,9(10),2661-2671","journal-title":"Bioorg Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.bbadis.2017.09.007","volume":"1863","author":"Leva G.","year":"2017","unstructured":"Leva G.; Klein C.; Benyounes J.; Hall\u00e9 F.; Bihel F.; Collongues N.; De Seze J.; Mensah-Nyagan A.G.; Patte-Mensah C.; The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL\/J mouse model of multiple sclerosis. Biochim Biophys Acta Mol Basis Dis 2017,1863(12),3016-3027","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/sj.bjp.0705681","volume":"142","author":"Kita A.","year":"2004","unstructured":"Kita A.; Kohayakawa H.; Kinoshita T.; Ochi Y.; Nakamichi K.; Kurumiya S.; Furukawa K.; Oka M.; Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol 2004,142(7),1059-1072","journal-title":"Br J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12017-016-8425-7","volume":"19","author":"Wang D.S.","year":"2017","unstructured":"Wang D.S.; Han J.; Li S.; Sun T.; Guo Y.Y.; Kang W.B.; Tian Z.; Zhao J.N.; Liu G.; Liu S.B.; Zhao M.G.; Antidepressant-like and anxiolytic-like effects of zbd-2, a novel ligand for the translocator protein (18 kDa). Neuromolecular Med 2017,19(1),57-68","journal-title":"Neuromolecular Med"},{"key":"ref=32","unstructured":"The advantages of pharmacophore modeling. Available from:   https:\/\/www.schrodinger.com\/phase"},{"key":"ref=33","first-page":"1363","volume":"343","author":"Jaremko \u0141.","year":"2014","unstructured":"Jaremko \u0141.; Jaremko M.; Giller K.; Becker S.; Zweckstetter M.;  Structure of the mitochondrial translocator protein in complex with a diagnostic ligand Science (80- ) 2014,343,1363-1366","journal-title":"Structure of the mitochondrial translocator protein in complex with a diagnostic ligand Science (80- )"},{"key":"ref=34","author":"Schr\u00f6dinger  Release","year":"2015","unstructured":"Schr\u00f6dinger Release;  2015-4: Maestro, Version 104 2015","journal-title":"2015-4: Maestro, Version 104"},{"key":"ref=35","first-page":"304","author":"Seredenin S.B.","year":"1994","unstructured":"Seredenin S.B.; Longo V.; Gaviraghi G.;  Biological basis of individual sensitivity to psychotropic drugs 1994,304","journal-title":"Biological basis of individual sensitivity to psychotropic drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0091-3057(90)90125-2","volume":"36","author":"Bruhwyler J.","year":"1990","unstructured":"Bruhwyler J.; Chleide E.; Li\u00e9geois J.F.; Delarge J.; Mercier M.; Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test. Pharmacol Biochem Behav 1990,36(1),57-61","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0166-4328(01)00292-3","volume":"125","author":"File S.E.","year":"2001","unstructured":"File S.E.; Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 2001,125(1-2),151-157","journal-title":"Behav Brain Res"},{"key":"ref=38","author":"Schr\u00f6dinger Release","year":"2015","unstructured":"Schr\u00f6dinger Release;  2015-2: LigPrep 2015","journal-title":"2015-2: LigPrep"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210806095051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195344\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210806095051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T06:48:13Z","timestamp":1666939693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195344\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406417666210806095051","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}